Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first ...

Winnacunnet High School senior Joe Labrecque has transformed his battle with a rare chronic illness into a mission to help others.

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

The global market for generalized myasthenia gravis management is poised for sustained ... this uptrend is largely fueled by an increase in autoimmune disease prevalence, advancements in diagnostic ...

Myasthenia gravis (MG) is a rare ... including the treatment of other autoimmune diseases driven by Th17-mediated inflammation. However, researchers caution that further work is needed to evaluate ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a ...

Generalized myasthenia gravis (gMG) is a chronic autoimmune disorder driven by the classical pathway that causes progressive muscle weakness. Over 100,000 people in the US are living with gMG and ...